4qfc: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
''' | ==Co-crystal structure of compound 3 (4-hydroxy-6-[2-(7-hydroxy-2-oxo-4-phenyl-2h-chromen-6-yl)ethyl]pyridazin-3(2h)-one) and FAD bound to human DAAO at 2.4A== | ||
<StructureSection load='4qfc' size='340' side='right' caption='[[4qfc]], [[Resolution|resolution]] 2.40Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>[[4qfc]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4QFC OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4QFC FirstGlance]. <br> | |||
</td></tr><tr><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=31T:4-HYDROXY-6-[2-(7-HYDROXY-2-OXO-4-PHENYL-2H-CHROMEN-6-YL)ETHYL]PYRIDAZIN-3(2H)-ONE'>31T</scene>, <scene name='pdbligand=FAD:FLAVIN-ADENINE+DINUCLEOTIDE'>FAD</scene>, <scene name='pdbligand=K:POTASSIUM+ION'>K</scene><br> | |||
<tr><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4qfd|4qfd]]</td></tr> | |||
<tr><td class="sblockLbl"><b>Activity:</b></td><td class="sblockDat"><span class='plainlinks'>[http://en.wikipedia.org/wiki/D-amino-acid_oxidase D-amino-acid oxidase], with EC number [http://www.brenda-enzymes.info/php/result_flat.php4?ecno=1.4.3.3 1.4.3.3] </span></td></tr> | |||
<tr><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4qfc FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4qfc OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4qfc RCSB], [http://www.ebi.ac.uk/pdbsum/4qfc PDBsum]</span></td></tr> | |||
<table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
The N-methyl-D-aspartate receptor (NMDAR) is a central regulator of synaptic plasticity and learning and memory. Human D-amino acid oxidase (hDAAO) indirectly reduces NMDAR activity by degrading the NMDAR co-agonist D-serine. Because NMDAR hypofunction is thought to be a foundational defect in schizophrenia, hDAAO inhibitors have potential as treatments for schizophrenia and other nervous system disorders. Here, we sought to identify novel chemicals that inhibit hDAAO activity. We used computational tools to design a focused, purchasable library of compounds. After screening this library for hDAAO inhibition, we identified the structurally novel compound 3-(7-Hydroxy-2-oxo-4-phenyl-2H-chromen-6-yl)propanoic acid ("compound 2"), which displayed low nM hDAAO inhibitory potency (Ki = 7 nM). While the library was expected to enrich for compounds that were competitive for both D-serine and flavin adenine dinucleotide (FAD), compound 2 actually was FAD uncompetitive, much like canonical hDAAO inhibitors such as benzoic acid. Compound 2 and an analog were independently co-crystalized with hDAAO. These compounds stabilized a novel conformation of hDAAO in which the active site lid was in an open position. These results confirm previous hypotheses regarding active site lid flexibility of mammalian D-amino acid oxidases and could assist in the design of the next generation of hDAAO inhibitors. | |||
Novel Human D-Amino Acid Oxidase Inhibitors Stabilize an Active Site Lid Open Conformation.,Terry-Lorenzo RT, Chun LE, Brown SP, Heffernan ML, Fang QK, Orsini MA, Pollegioni L, Hardy LW, Spear KL, Large TH Biosci Rep. 2014 Jul 8. PMID:25001371<ref>PMID:25001371</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
</div> | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: D-amino-acid oxidase]] | |||
[[Category: Chun, L.]] | |||
[[Category: Lukacs, C M.]] | |||
[[Category: D-amino acid oxidase]] | |||
[[Category: D-serine competitive]] | |||
[[Category: Daao]] | |||
[[Category: Fad dependent]] | |||
[[Category: Nmdar]] | |||
[[Category: Oxidase]] | |||
[[Category: Oxidoreductase]] | |||
[[Category: Oxidoreductase-oxidoreductase inhibitor complex]] | |||
[[Category: Schizophrenia]] | |||
Revision as of 13:20, 16 July 2014
Co-crystal structure of compound 3 (4-hydroxy-6-[2-(7-hydroxy-2-oxo-4-phenyl-2h-chromen-6-yl)ethyl]pyridazin-3(2h)-one) and FAD bound to human DAAO at 2.4ACo-crystal structure of compound 3 (4-hydroxy-6-[2-(7-hydroxy-2-oxo-4-phenyl-2h-chromen-6-yl)ethyl]pyridazin-3(2h)-one) and FAD bound to human DAAO at 2.4A
Structural highlights
Publication Abstract from PubMedThe N-methyl-D-aspartate receptor (NMDAR) is a central regulator of synaptic plasticity and learning and memory. Human D-amino acid oxidase (hDAAO) indirectly reduces NMDAR activity by degrading the NMDAR co-agonist D-serine. Because NMDAR hypofunction is thought to be a foundational defect in schizophrenia, hDAAO inhibitors have potential as treatments for schizophrenia and other nervous system disorders. Here, we sought to identify novel chemicals that inhibit hDAAO activity. We used computational tools to design a focused, purchasable library of compounds. After screening this library for hDAAO inhibition, we identified the structurally novel compound 3-(7-Hydroxy-2-oxo-4-phenyl-2H-chromen-6-yl)propanoic acid ("compound 2"), which displayed low nM hDAAO inhibitory potency (Ki = 7 nM). While the library was expected to enrich for compounds that were competitive for both D-serine and flavin adenine dinucleotide (FAD), compound 2 actually was FAD uncompetitive, much like canonical hDAAO inhibitors such as benzoic acid. Compound 2 and an analog were independently co-crystalized with hDAAO. These compounds stabilized a novel conformation of hDAAO in which the active site lid was in an open position. These results confirm previous hypotheses regarding active site lid flexibility of mammalian D-amino acid oxidases and could assist in the design of the next generation of hDAAO inhibitors. Novel Human D-Amino Acid Oxidase Inhibitors Stabilize an Active Site Lid Open Conformation.,Terry-Lorenzo RT, Chun LE, Brown SP, Heffernan ML, Fang QK, Orsini MA, Pollegioni L, Hardy LW, Spear KL, Large TH Biosci Rep. 2014 Jul 8. PMID:25001371[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. References
|
| ||||||||||||||||||||